ENTRY       D05029                      Drug
NAME        Midostaurin (JAN/USAN/INN);
            Rydapt (TN)
PRODUCT     RYDAPT (Novartis Pharmaceuticals Corporation)
FORMULA     C35H30N4O4
EXACT_MASS  570.2267
MOL_WEIGHT  570.6371
CLASS       Antineoplastic
             DG01918  Tyrosine kinase inhibitor
              DG01917  Receptor tyrosine kinase inhibitor
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      ATC code: L01EX10
            Product: D05029<US>
EFFICACY    Antineoplastic, Receptor tyrosine kinase inhibitor
  DISEASE   Acute myeloid leukemia (FLT3 mutation-positive) [DS:H00003]
            Systemic mastocytosis [DS:H01511]
TARGET      FLT3* (CD135) [HSA_VAR:2322v1 2322v2] [HSA:2322] [KO:K05092]
            KIT (CD117) [HSA:3815] [KO:K05091]
            PDGFR [HSA:5156 5159] [KO:K04363 K05089]
            VEGFR2 (KDR) [HSA:3791] [KO:K05098]
            PRKCA [HSA:5578] [KO:K02677]
            PRKCB [HSA:5579] [KO:K19662]
            PRKCG [HSA:5582] [KO:K19663]
  PATHWAY   hsa04010(2322+3791+3815+5156+5159+5578+5579+5582)  MAPK signaling pathway
            hsa04151(2322+3791+3815+5156+5159+5578)  PI3K-Akt signaling pathway
            hsa04370(3791+5578+5579+5582)  VEGF signaling pathway
            hsa04670(5578+5579+5582)  Leukocyte transendothelial migration
            hsa05200(2322+3815+5156+5159+5578+5579+5582)  Pathways in cancer
            hsa05221(2322+3815)  Acute myeloid leukemia
METABOLISM  Enzyme: CYP3A4 [HSA:1576]
INTERACTION  
STR_MAP     map07045  Antineoplastics - protein kinase inhibitors
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01E PROTEIN KINASE INHIBITORS
                L01EX Other protein kinase inhibitors
                 L01EX10 Midostaurin
                  D05029  Midostaurin (JAN/USAN/INN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Molecular Target Inhibitors
               Midostaurin
                D05029  Midostaurin (JAN/USAN/INN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG01918  Tyrosine kinase inhibitor
               DG01917  Receptor tyrosine kinase inhibitor
                D05029  Midostaurin
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                D05029  Midostaurin
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Serine/threonine kinases
               AGC group
                PRKCA
                 D05029  Midostaurin (JAN/USAN/INN) &lt;US&gt;
                PRKCB
                 D05029  Midostaurin (JAN/USAN/INN) &lt;US&gt;
                PRKCG
                 D05029  Midostaurin (JAN/USAN/INN) &lt;US&gt;
              Receptor tyrosine kinases (RTK)
               PDGFR family
                PDGFR
                 D05029  Midostaurin (JAN/USAN/INN) &lt;US&gt;
                KIT (CD117)
                 D05029  Midostaurin (JAN/USAN/INN) &lt;US&gt;
                FLT3* (CD135) [HSA_VAR:2322v1 2322v2]
                 D05029  Midostaurin (JAN/USAN/INN) &lt;US&gt;
               VEGFR family
                VEGFR2 (KDR)
                 D05029  Midostaurin (JAN/USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D05029
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D05029
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D05029
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D05029
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D05029
DBLINKS     CAS: 120685-11-2
            PubChem: 47206756
            ChEBI: 63452
            PDB-CCD: 2K2
            LigandBox: D05029
            NIKKAJI: J492.319G
ATOM        43
            1   C8y C    18.3242  -20.7759
            2   C8y C    18.3250  -22.1603
            3   C8y C    19.5242  -22.8517
            4   C8y C    20.7229  -22.1589
            5   C8y C    20.7221  -20.7745
            6   C8y C    19.5226  -20.0830
            7   C5x C    17.0074  -20.3488
            8   N1x N    16.1942  -21.4692
            9   C1x C    17.0087  -22.5887
            10  N4y N    21.7504  -19.8475
            11  C8y C    21.1867  -18.5831
            12  C8y C    19.8097  -18.7287
            13  C8y C    19.8129  -24.2056
            14  C8y C    21.1900  -24.3496
            15  N4y N    21.7523  -23.0845
            16  O5x O    16.5825  -19.0442
            17  C8x C    21.7489  -17.3182
            18  C8x C    20.9345  -16.1987
            19  C8x C    19.5577  -16.3442
            20  C8x C    18.9954  -17.6092
            21  C8x C    18.9999  -25.3261
            22  C8x C    19.5636  -26.5903
            23  C8x C    20.9406  -26.7343
            24  C8x C    21.7537  -25.6139
            25  C1y C    23.1429  -20.1421
            26  C1z C    23.1444  -22.7884
            27  O2x O    22.4435  -21.4950
            28  C1x C    24.5430  -20.1413
            29  C1y C    24.5445  -22.7876
            30  C1y C    25.2652  -21.4662
            31  C1a C    23.2886  -24.1489
            32  O2a O    25.2374  -23.9849
            33  N1c N    26.6718  -21.4976
            34  C1a C    24.5187  -25.2340
            35  C1a C    27.3420  -22.7208
            36  C5a C    27.4015  -20.2966
            37  C8y C    26.7238  -19.0595
            38  O5a O    28.7710  -20.3274
            39  C8x C    27.4635  -17.8425
            40  C8x C    26.7907  -16.6146
            41  C8x C    25.3910  -16.5832
            42  C8x C    24.6514  -17.8003
            43  C8x C    25.3241  -19.0281
BOND        51
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     1   7 1
            8     7   8 1
            9     8   9 1
            10    2   9 1
            11    5  10 1
            12   10  11 1
            13   11  12 1
            14    6  12 1
            15    3  13 1
            16   13  14 1
            17   14  15 1
            18    4  15 1
            19    7  16 2
            20   11  17 2
            21   17  18 1
            22   18  19 2
            23   19  20 1
            24   12  20 2
            25   13  21 2
            26   21  22 1
            27   22  23 2
            28   23  24 1
            29   14  24 2
            30   10  25 1
            31   15  26 1
            32   25  27 1
            33   27  26 1
            34   25  28 1
            35   26  29 1
            36   29  30 1
            37   28  30 1
            38   26  31 1 #Down
            39   29  32 1 #Up
            40   30  33 1 #Up
            41   32  34 1
            42   33  35 1
            43   33  36 1
            44   36  37 1
            45   36  38 2
            46   37  39 2
            47   39  40 1
            48   40  41 2
            49   41  42 1
            50   42  43 2
            51   37  43 1
///
